Business Context and Reporting Period
Capstone Therapeutics Corp., a development-stage biotechnology company, filed this unaudited Form 10-Q for the quarter and six months ended June 30, 2013. The filing identifies the registrant as Capstone Therapeutics Corp.; the request metadata references Capstone Holding Corp.
- The company develops peptide-based therapies for underserved medical conditions.
- Internal operations were reduced to a virtual operating model, with two employees, following the 2012 wind-down of AZX100 dermal-scarring clinical development.
- The principal active initiative is AEM-28 and related Apo E mimetic molecules, developed through the 60%-owned LipimetiX Development LLC joint venture.
- AZX100 development and partnering opportunities continue on a limited basis. The company has no remaining rights to Chrysalin.
Financial Highlights
| Metric | Three Months Ended June 30, 2013 | Three Months Ended June 30, 2012 | Six Months Ended June 30, 2013 | Six Months Ended June 30, 2012 |
|---|---|---|---|---|
| Revenue | No revenue reported | No revenue reported | No revenue reported | No revenue reported |
| General and administrative expense | $277,000 | $393,000 | $711,000 | $817,000 |
| Research and development expense | $749,000 | $403,000 | $1,661,000 | $959,000 |
| Operating expenses | $1.026 million | $796,000 | $2.372 million | $1.776 million |
| Net loss attributable to Capstone stockholders | $1.008 million | $712,000 | $2.004 million | $1.688 million |
| Basic and diluted loss per share | $0.02 | $0.02 | $0.05 | $0.04 |
| Cash flow from operating activities | Not separately reported | Not separately reported | $(2.086) million | $(1.124) million |
- There is no meaningful gross or operating margin because the company reported no revenue.
- Cash and cash equivalents were $8.123 million at June 30, 2013, down from $10.205 million at December 31, 2012. Approximately $3.073 million was held by and reserved for LipimetiX and was unavailable for general corporate use.
- Total assets were $9.229 million, compared with $11.591 million at December 31, 2012.
- Current liabilities were $101,000, compared with $294,000 at year-end 2012. The filing does not report debt outstanding.
- Stockholders’ equity was $9.128 million at June 30, 2013, compared with $11.104 million at December 31, 2012. The accumulated deficit was $180.101 million, including $152.339 million incurred during the development-stage period.
- Cash used in investing activities was $4,000 during the first six months of 2013, and there were no financing cash flows.
Material Changes Versus the Prior Comparable Period
- Second-quarter research and development expense increased $346,000, primarily because LipimetiX operating expenses of $584,000 were included in 2013.
- Six-month research and development expense increased $702,000, including $1.415 million of LipimetiX operating expenses.
- General and administrative expense decreased $106,000 for the first six months, reflecting lower lease costs and reduced staffing.
- Second-quarter net loss increased to $1.008 million from $712,000; six-month net loss attributable to Capstone stockholders increased to $2.004 million from $1.688 million.
- Operating cash burn increased to $2.086 million for the first six months from $1.124 million in the prior-year period.
- Interest and other income, net was $154,000 for the first six months of 2013 versus $88,000 in 2012, primarily due to a $152,000 payment related to the conversion of an insurance company in which the company was a policyholder.
Guidance, Outlook, Risks, Contingencies, and Unusual Items
- Management estimated 2013 expenditures of approximately $4.0 million, including approximately $2.5 million by LipimetiX, excluding potentially significant qui tam litigation costs.
- Management expected cash and short-term investments at June 30, 2013 to fund presently projected requirements for the next twelve months.
- Additional substantial capital would be required to complete clinical trials and related research, manufacturing, and regulatory activities needed for potential FDA approvals. Potential funding sources include equity or debt issuance, joint development arrangements, asset or development-rights sales, and licensing transactions.
- LipimetiX’s initial development plan contemplated approximately 27 months of work through Phase 1a and Phase 1b/2a trials for AEM-28. The joint venture had approximately $3.1 million remaining from its initial $6.0 million funding at June 30, 2013.
- After March 31, 2013, all LipimetiX losses were allocated to Capstone because common ownership equity had been reduced to zero. The noncontrolling owners were not required to contribute additional funds, creating potential for Capstone to absorb future joint-venture losses.
- The company faces a qui tam lawsuit concerning its former bone-device business. The plaintiff seeks civil penalties and treble damages that could exceed the company’s financial resources. Management believed a material loss was not reasonably possible based on available information, but acknowledged substantial uncertainty and could not estimate future litigation costs.
- Key development risks include unsuccessful preclinical or clinical results, FDA delays or rejection, increased regulation, competition, intellectual-property impairment, failure to execute the AEM-28 strategy, inability to obtain funding, and the impact of litigation on liquidity and operations.
- Management reported effective disclosure controls and no material changes to internal control over financial reporting. The filing states that there were no material changes to previously disclosed risk factors.
Important Facts for Investors to Verify
- Verify the registrant’s legal name and corporate identity, given the metadata reference to Capstone Holding Corp. and the filing’s identification of Capstone Therapeutics Corp.
- Confirm the availability of cash for general corporate purposes after excluding the $3.073 million reserved for LipimetiX.
- Assess whether the projected cash runway remains adequate in light of continued operating losses, joint-venture spending, and unquantified litigation costs.
- Review the status, funding, regulatory milestones, and clinical progress of AEM-28 and the LipimetiX joint venture.
- Evaluate the potential financial exposure from the qui tam action, including damages, penalties, defense costs, and effects on the company’s ability to continue operations.
- Review the company’s need for future capital and the possible dilution or unfavorable terms associated with financing or licensing transactions.
- Consider the lack of revenue, substantial accumulated deficit, development-stage status, and dependence on successful product development or partnering.